This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2004 Remove Competition Remove Pharmaceutical products
article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

JUNE 24, 2022

Stakeholders in the EU often use the risk-adjusted Net Present Value (rNPV) investment model to determine whether to invest in a pharmaceutical product. He focuses his practice on EU regulatory affairs, litigation and competition law issues affecting the life sciences sector in Europe. About the author. References.

Pharmaceutical 105
Pharmaceutical Medicine Marketing Competition 105
article thumbnail

Uri Goren

Cadensee

JULY 20, 2021

When he was going through his cancer, he died in 2004. But there's a lot of other things that bother patients and might be a target for healthcare technology, or pharmaceutical products. But in terms of Israel as a competitive advantage, I think data is much more than just good technology.

Food and Drug Administration 52
Food and Drug Administration Doctors Healthcare Healthcare 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
Webinars
About
Editions
Webinars
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024